Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- The quote is verbatim operative text from 21 CFR 202.1(e)(6)(xviii), an enumerated clause under the sentence 'An advertisement for a prescription drug is false, lacking in fair balance, or otherwise misleading... if it:'. It is a binding prohibition, not an example or definition, so the rule statement follows from the source.
- Severity 'blocker' is defensible: (e)(6) is the definitive list (contrast (e)(7), which uses the weaker 'may be false'), and paragraph (k) provides that a non-compliant advertisement causes the drug to be misbranded under section 502(n).
- 'judgment' is correct — 'in a way that is misleading' depends on conveyed impression, not on presence/absence or literal match.
- 'binding' is correct — this is a codified federal regulation.
- Atomic is acceptable: although three element types are named, the clause expresses one prohibition under one test; splitting headline from graphic would not yield independently checkable obligations.
- Locator 21 CFR 202.1(e)(6)(xviii) is accurate for the quoted sentence.
- Overstated on scope: applies_when is a bare 'promotional', but the governing sentence of (e)(6) limits the list to 'an advertisement for a prescription drug'. As written the rule would fire on OTC material and on promotional pieces outside the advertising definition, which this clause does not cover.
- Overstated in the check: 'Evaluate headlines and graphics independently of body text for standalone misleading impressions' imposes a standalone-evaluation methodology that the regulation does not state. The source asks only whether the element is 'used in a way that is misleading'; the neighboring clause (e)(7)(iv) similarly addresses the impression created, not isolation from surrounding copy.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — pass
claude-opus-5 · 2026-09-21
Reviewer's reasons
- The quote is an operative subparagraph of the enumerated list in 21 CFR 202.1(e)(6), whose chapeau states that 'An advertisement for a prescription drug is false, lacking in fair balance, or otherwise misleading, or otherwise violative of section 502(n) of the act, among other reasons, if it: ... (xviii) Uses headline, subheadline, or pictorial or other graphic matter in a way that is misleading.' This is a definitional/operative prohibition, not an example, definition-only passage, or preamble; the rule statement tracks it closely.
- Not overstated: the rule mirrors the (e)(6) list (things an ad 'is' misleading for doing), not the weaker (e)(7) 'may be' list, so stating it as a prohibition is correct. The rule statement preserves the source's scope limit to advertisements for prescription drugs rather than generalizing to all promotional materials.
- Atomic: headline, subheadline, and pictorial/other graphic matter are alternative triggers of a single obligation (do not use them misleadingly), not independently checkable distinct requirements; a reviewer performs one assessment of whether any such element is used misleadingly.
- Determinism 'judgment' is correct — the operative term is 'in a way that is misleading', which turns on the impression conveyed, not on presence/absence or literal text matching. The escalation note appropriately flags reviewer disagreement on overall impression.
- Authority 'binding' is correct: 21 CFR 202.1 is a codified FDA regulation, and (k) provides that a noncompliant advertisement causes the drug to be misbranded under section 502(n).
- Severity 'blocker' is defensible: a violation of (e)(6) renders the advertisement false/misleading and misbranding under 502(n); the only relief in the source is an FDA-granted written waiver, which is not something a reviewer can assume.
- Locator 21 CFR 202.1(e)(6)(xviii) is exact, and applies_when (promotional; drug) is justified by the chapeau's limitation to prescription drug advertisements, with the prescription-drug/advertisement limit carried in the rule statement itself.